- Home
- MYNZ
MYNZ
Mainz Biomed N.V.
as 12-18-2024 4:00pm EST
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
| Founded: | 2021 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 11.2M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 128.8K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -44.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $7.95 | Next Earning Date: | 10-21-2024 |
| Revenue: | $917,203 | Revenue Growth: | 16.23% |
| Revenue Growth (this year): | 36.69% | Revenue Growth (next year): | 91.67% |
Latest Mainz Biomed N.V. News
MYNZ Breaking Stock News: Dive into MYNZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
GlobeNewswire
6 days ago
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
MT Newswires
19 days ago
Mainz Biomed to Implement 1-for-40 Reverse Stock Split
GlobeNewswire
19 days ago
Mainz Biomed Announces Stock Split
Benzinga
a month ago
The Oncology Bet Is Already Paying Off For Pfizer
MT Newswires
a month ago
Mainz Biomed, Thermo Fisher Partner to Develop Colorectal Cancer Screening Test
GlobeNewswire
a month ago
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
TipRanks
2 months ago
Mainz Biomed restructured operations, implemented cost reductions
Compare MYNZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYNZ Mainz Biomed N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.